To test the efficacy of M3814 in combination with topoisomerase II inhibitors, we performed in vivo xenograft studies using cell lines representative of P53 wild-type ovarian cancer (A2780), and P53 mutant ovarian cancer (SKOV3). This evidence concerns the gene TP53 and ovarian carcinoma.